Details for Patent: 9,926,559

Which drugs does patent 9,926,559 protect, and when does it expire?

Patent 9,926,559 protects SPINRAZA and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 9,926,559

Patent landscape, scope, and claims:

Title:	Compositions and methods for modulation of SMN2 splicing in a subject
Abstract:	Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
Inventor(s):	Bennett; C. Frank (Carlsbad, CA), Hung; Gene (San Diego, CA), Rigo; Frank (Carlsbad, CA)
Assignee:	Biogen MA Inc. (Cambridge, MA)
Application Number:	14/760,171
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,926,559

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Biogen Idec	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016		RX	Yes	Yes	9,926,559					TREATMENT OF SPINAL MUSCULAR ATROPHY

Foreign Priority and PCT Information for Patent: 9,926,559

PCT Information
PCT Filed	January 09, 2014	PCT Application Number:	PCT/US2014/010930
PCT Publication Date:	July 17, 2014	PCT Publication Number:	WO2014/110291

International Family Members for US Patent 9,926,559

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2943225
World Intellectual Property Organization (WIPO)	2014110291